Our Pipeline

Our integrative discovery platform combines functional screening with an effect-driven research approach to advance programs in immunology and immuno-oncology.

For cancer, our pipeline holds first- and second-generation immune activators, that have synergy with checkpoint inhibitors and can help to target a wide range of challenging malignancies. Our small molecules show a unique safety profile and better drug-like properties with oral bioavailability and efficient tissue penetration.